CTMX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
CytomX Therapeutics, Inc. had $76.2M of revenue in fiscal 2025, down 44.8% on the year before. Over five years, revenue changed +2.2% a year on average.
Last close Β· Oct 23, 2026
$2.32
4.9%Hi! I read CytomX Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β44.8%
No. Sales fell 44.8% last year.
Does it make a profit?
β22.8%
No. It lost money last year.
Does profit turn into cash?
β99.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days CytomX Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 7, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 16, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 6, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 7, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 12, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 6, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 7, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· CytomX Therapeutics, Inc. had $76.2M of revenue in fiscal 2025, down 44.8% on the year before. Over five years, revenue changed +2.2% a year on average. Its operating margin was β29.3%, down 47.4Β pts: of every 100 in sales, about β29 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· CytomX Therapeutics, Inc. lost $17.4M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$75.8M in fiscal 2025, β99.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably CytomX Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $305M | $194M | $175M | $101M | $137M |
| Current ratio | 4.0x | 1.6x | 1.2x | 1.3x | 3.1x |
| Quick ratio | 4.0x | 1.6x | 1.2x | 1.3x | 3.1x |
| Total assets | $339M | $261M | $202M | $121M | $152M |
| Total liabilities | $340M | $347M | $249M | $121M | $52.6M |
| Shareholders' equity | β$0.5M | β$85.8M | β$47.4M | β$0.5M | $99.0M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· CytomX Therapeutics, Inc. passes 1 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 7 | 1 / 7 | 0 / 7 | 5 / 7 | 0 / 7 | 1 / 7 | 2 / 7 | 4 / 7 | 1 / 7 |
| Accruals ratio | β28.6% | β71.5% | β2.1% | 1.9% | β20.0% | 0.9% | 3.8% | 24.0% | 73.3% | 42.8% |
| Altman Z'' | 0.80 | 3.05 | 2.03 | β2.74 | β1.47 | β3.80 | β9.78 | β11.22 | β16.14 | β10.12 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $15.0M | $71.6M | $59.5M | $26.9M | $68.4M | $37.3M | $53.2M | $101M | $138M | $76.2M |
| Research and development | $54.8M | $92.3M | $104M | $132M | $113M | $114M | $112M | $77.7M | $83.4M | $68.7M |
| Operating income | β$59.6M | β$46.3M | β$77.9M | β$141M | β$80.5M | β$116M | β$101M | β$6.5M | $25.0M | β$22.4M |
| Interest expense | $1.7M | β | β | β | β | β | β | β | β | β |
| Pretax income | β$58.9M | β$43.6M | β$70.3M | β$133M | β$78.7M | β$116M | β$99.3M | $3.3M | $32.1M | β$17.1M |
| Income tax | β$0.0M | β$0.5M | $14.3M | β$0.4M | β$13.9M | $0.0M | $0.0M | $3.9M | $0.2M | $0.2M |
| Net income | β$58.9M | β$43.1M | β$84.6M | β$133M | β$64.8M | β$116M | β$99.3M | β$0.6M | $31.9M | β$17.4M |
| Net income to common | β$58.9M | β$43.1M | β | β | β | β | β | β | $31.9M | β$20.4M |
| Diluted EPS | β$1.63 | β$1.16 | β | β | β | β | β | β | β | β |
| Diluted shares | 0.04B | 0.04B | 0.04B | 0.05B | 0.05B | 0.06B | 0.07B | 0.07B | 0.08B | 0.14B |
| Cash flow | ||||||||||
| Cash from operations | β$2.0M | $170M | β$75.5M | β$140M | $5.3M | β$119M | β$111M | β$56.0M | β$86.2M | β$75.6M |
| Capital expenditure | $2.2M | $1.6M | $3.8M | $3.5M | $2.3M | $1.6M | $1.7M | $0.8M | $0.3M | $0.2M |
| Free cash flow | β$4.2M | $169M | β$79.3M | β$144M | $3.0M | β$121M | β$113M | β$56.9M | β$86.5M | β$75.8M |
| Depreciation and amortization | $1.7M | $1.6M | $1.9M | $2.5M | $2.4M | $2.6M | $2.3M | $2.0M | $1.6M | $1.2M |
| Stock-based compensation | $10.1M | $11.3M | $16.9M | $19.1M | $14.8M | $13.2M | $13.1M | $8.6M | $7.7M | $6.3M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $105M | $374M | $436M | $296M | $316M | $305M | $194M | $175M | $101M | $137M |
| Current assets | $188M | $389M | $445M | $303M | $324M | $310M | $237M | $183M | $107M | $144M |
| Current liabilities | $35.8M | $61.1M | $97.9M | $85.6M | $68.1M | $77.9M | $153M | $156M | $85.8M | $46.6M |
| Property and equipment, net | $4.4M | $4.2M | $6.9M | $7.4M | $7.0M | $6.0M | $5.1M | $4.0M | $2.5M | $1.3M |
| Goodwill | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M |
| Total assets | $199M | $398M | $457M | $341M | $359M | $339M | $261M | $202M | $121M | $152M |
| Total liabilities | $121M | $328M | $326M | $290M | $366M | $340M | $347M | $249M | $121M | $52.6M |
| Preferred stock | β | β | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $78.5M | $69.9M | $136M | $25.5M | β$7.8M | β$0.5M | β$85.8M | β$47.4M | β$0.5M | $99.0M |
| Margins | ||||||||||
| Operating margin | β396.1% | β64.6% | β130.9% | β525.9% | β117.7% | β311.0% | β190.6% | β6.4% | 18.1% | β29.3% |
| EBITDA margin | β384.6% | β62.3% | β127.7% | β516.6% | β114.2% | β304.0% | β186.3% | β4.4% | 19.3% | β27.8% |
| Net margin | β391.5% | β60.2% | β142.2% | β493.7% | β94.7% | β310.5% | β186.8% | β0.6% | 23.1% | β22.8% |
| FCF margin | β28.0% | 235.7% | β133.3% | β535.2% | 4.3% | β323.3% | β211.7% | β56.2% | β62.7% | β99.5% |
| Returns | ||||||||||
| Return on capital employed | β36.5% | β13.7% | β21.7% | β55.3% | β27.7% | β44.4% | β93.6% | β14.1% | 71.9% | β21.3% |
| Return on equity | β75.1% | β58.1% | β82.3% | β164.7% | β732.6% | β | β | β | β | β35.2% |
| Return on assets | β29.6% | β14.4% | β19.8% | β33.3% | β18.5% | β33.2% | β33.1% | β0.2% | 19.8% | β12.8% |
| Return on tangible equity | β76.0% | β62.5% | β62.7% | β541.7% | β | β | β | β | β | β20.8% |
| Growth | ||||||||||
| Revenue growth | β | 376.1% | β16.9% | β54.8% | 154.4% | β45.5% | 42.5% | 90.4% | 36.4% | β44.8% |
| Net income growth | β | β | β | β | β | β | β | β | β | β154.5% |
| FCF growth | β | β | β147.0% | β | β | β4,189.5% | β | β | β | β |
| Share count change | β | 2.6% | 12.1% | 8.8% | 1.8% | 39.0% | 2.5% | 12.3% | 14.8% | 62.8% |
| Financial health | ||||||||||
| Interest coverage | β35.3x | β | β | β | β | β | β | β | β | β |
| Current ratio | 5.3x | 6.4x | 4.5x | 3.5x | 4.8x | 4.0x | 1.6x | 1.2x | 1.3x | 3.1x |
| Quick ratio | 5.3x | 6.4x | 4.5x | 3.5x | 4.8x | 4.0x | 1.6x | 1.2x | 1.3x | 3.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 14.5% | 2.2% | 6.4% | 13.0% | 3.4% | 4.3% | 3.3% | 0.8% | 0.2% | 0.3% |
| Stock comp / revenue | 67.1% | 15.8% | 28.4% | 71.0% | 21.6% | 35.3% | 24.7% | 8.5% | 5.6% | 8.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 1.0 | 0.0 | 5.0 | 0.0 | 1.0 | 2.0 | 4.0 | 1.0 |
| Altman Z'' | 0.8 | 3.0 | 2.0 | β2.7 | β1.5 | β3.8 | β9.8 | β11.2 | β16.1 | β10.1 |
| Accruals ratio | β28.6% | β71.5% | β2.1% | 1.9% | β20.0% | 0.9% | 3.8% | 24.0% | 73.3% | 42.8% |
Source: SEC EDGAR XBRL filings (CIK 0001501989). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
